Invariantum

Biology is shifting toward data, AI, and simulation. The real value is in platforms and compute, while robotics speeds progress. Traditional biotech offers lower, less scalable returns.

FHE enables computation on encrypted data, eliminating decryption risks. Hardware acceleration (e.g. Intel Heracles) may make it economic viable, unlocking massive markets across AI, cloud, healthcare, and finance.

Meta’s AI spending is not about creating a new business, but strengthening its core advertising engine. If incremental efficiency gains pers

Elevated S&P 500 valuations hinge on the durability of corporate margins, shaped by structural scalability, monetary conditions, and AI, rather than solely by traditional valuation metrics like CAPE.

Hermès at lower valuation multiples may serve as a structural hedge against automation, supported by scarcity-driven economics, hierarchy-based demand, strong margins, and durable cultural positioning.

Microsoft’s 30% correction reflects multiple compression amid heavy AI capex, not operational weakness. Revenue, margins, and cash flow remain strong; the debate centers on returns from infrastructure investment.